Open Orphan PLC Investor Event Attendance and Presentation
08 Octobre 2019 - 8:00AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
08 October 2019
8 October 2019
Open Orphan Plc
("Open Orphan" or the "Company")
Investor Event Attendance and Presentation
Open Orphan presents at Shares Investor Evening, Manchester
Open Orphan, a European-focussed, rare and orphan drug
consulting services platform, is pleased to announce that the
Company will be attending and presenting at Shares Investor Evening
at Macdonald Manchester Hotel, Manchester, M1 2PG from 18:00 on
Thursday 10(th) October.
Cathal Friel, Open Orphan's Chief Executive Officer, will be in
attendance and will be presenting to update existing and potential
investors on the Company's business plans for 2019.
The event will provide an opportunity for investors to hear
about the progress being made by the Company following the reverse
takeover of Venn Life Sciences and the potential for Open Orphan
moving forward.
A link to the presentation will be made available on the Company
website following the event.
For further information on the event, please visit the event
website
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening-manchester-101019
Enquiries:
Open Orphan Plc Tel: +353 (0)1 6440007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focussed, rare and orphan drug
consulting services platform. The Company consists of four
elements: a European clinical research organisation and
consultancy; an orphan drug services business; a Virtual Rep and
Data Access Platform consisting of physicians and key opinion
leaders; and a Health Data Platform to partner with Patient
Advocacy Groups. The Company is targeting rapid growth in one of
the fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGGGUUUPBGQM
(END) Dow Jones Newswires
October 08, 2019 02:00 ET (06:00 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024